Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Targeting of PI3K/AKT signaling and DNA damage response in acute myeloid leukemia: a novel therapeutic strategy to boost chemotherapy response and overcome resistance

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. TET2 deficiency cooperates with CBFB-MYH11 to induce acute myeloid leukaemia and represents an early leukaemogenic event

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The EHA Research Roadmap: Normal Hematopoiesis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. MTH1 inhibitor TH1579 induces oxidative DNA damage and mitotic arrest in acute myeloid leukemia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
Resistance of cancer patients to DNA damaging radiation therapy and chemotherapy remains a major problem in the clinic. The current review discusses the molecular mechanisms of therapy resistance in acute myeloid leukemia (AML) conferred by cooperative chemotherapy-induced DNA damage response (DDR) and mutational activation of PI3K/AKT signaling. In addition, strategies to overcome resistance are discussed, with particular focus on studies underpinning the vast potential of therapies combining standard chemotherapy AML regimens with small molecule inhibitors targeting key regulatory hubs at the interface of DDR and oncogenic signaling pathways.
OriginalsprogEngelsk
TidsskriftCancer Drug Resistance
Vol/bind4
Sider (fra-til)984-95
Antal sider12
ISSN2578-532X
DOI
StatusUdgivet - 10 nov. 2021

ID: 71682101